inflammatory skin disease
Novartis’ Pluvicto approved by FDA for metastatic hormone-sensitive prostate cancer
More than 186,000 men are diagnosed each year with mHSPC globally
Novartis to acquire Myricx Bio in deal worth $1.5bn
Myricx, a UK-based biotech, is developing a new class of antibody-drug conjugates
Novartis breaks ground on US radioligand therapy site
The construction is part of the company’s investment in US research and manufacturing
Novartis to acquire Excellergy in deal worth up to $2bn
Exl-111, a potential treatment included in the deal, is a central factor in many allergic diseases
Scotland becomes first part of UK to screen all newborn babies for SMA
The screening is part of a two-year evaluation funded by the Scottish government and Novartis
Novartis agrees on potential $3bn deal to buy Synnovations’s breast cancer treatment
The oral drug is currently being evaluated for breast cancer and other advanced solid tumours in a phase 1/2 study
UCB releases new data on Bimzelx for hidradenitis suppurativa
The disease affects around 1% of the population in most studied countries
Novartis’ ianalumab receives FDA Breakthrough Therapy designation for Sjögren’s disease
Approximately half of those with Sjögren’s disease are thought to be undiagnosed
Novartis agrees to lower drug prices in deal with US government
In 2025, the pharma company announced a $23bn US investment commitment
Novartis’ Itvisma gets FDA approval for spinal muscular atrophy treatment
Around 9,000 people in the US currently live with SMA
Novartis announces plans for new US manufacturing hub
The US hub is expected to create 700 new jobs by 2030
Novartis reports primary endpoint reached in phase 3 malaria trial
The treatment demonstrated non-inferiority to current standard of care